293 related articles for article (PubMed ID: 22425622)
1. Diacylglycerol kinase alpha enhances hepatocellular carcinoma progression by activation of Ras-Raf-MEK-ERK pathway.
Takeishi K; Taketomi A; Shirabe K; Toshima T; Motomura T; Ikegami T; Yoshizumi T; Sakane F; Maehara Y
J Hepatol; 2012 Jul; 57(1):77-83. PubMed ID: 22425622
[TBL] [Abstract][Full Text] [Related]
2. Neuroglobin, a novel intracellular hexa-coordinated globin, functions as a tumor suppressor in hepatocellular carcinoma via Raf/MAPK/Erk.
Zhang J; Lan SJ; Liu QR; Liu JM; Chen XQ
Mol Pharmacol; 2013 May; 83(5):1109-19. PubMed ID: 23478801
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma.
Zhou SL; Dai Z; Zhou ZJ; Wang XY; Yang GH; Wang Z; Huang XW; Fan J; Zhou J
Hepatology; 2012 Dec; 56(6):2242-54. PubMed ID: 22711685
[TBL] [Abstract][Full Text] [Related]
4. Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma.
Hoffmann K; Shibo L; Xiao Z; Longerich T; Büchler MW; Schemmer P
Anticancer Res; 2011 Nov; 31(11):3883-90. PubMed ID: 22110214
[TBL] [Abstract][Full Text] [Related]
5. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration.
Chiu CY; Kuo KK; Kuo TL; Lee KT; Cheng KH
Mol Cancer Res; 2012 Mar; 10(3):415-27. PubMed ID: 22241220
[TBL] [Abstract][Full Text] [Related]
6. Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma.
Chen L; Shi Y; Jiang CY; Wei LX; Wang YL; Dai GH
Eur J Surg Oncol; 2011 Jun; 37(6):513-20. PubMed ID: 21324414
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
8. Expression and prognostic significance of vascular endothelial growth factor receptor 1 in hepatocellular carcinoma.
Li T; Zhu Y; Qin CY; Yang Z; Fang A; Xu S; Ren W
J Clin Pathol; 2012 Sep; 65(9):808-14. PubMed ID: 22734007
[TBL] [Abstract][Full Text] [Related]
9. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
10. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
11. OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway.
Li H; Miao Q; Xu CW; Huang JH; Zhou YF; Wu MJ
J Korean Med Sci; 2016 Aug; 31(8):1215-23. PubMed ID: 27478331
[TBL] [Abstract][Full Text] [Related]
12. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors.
Yoshida T; Hisamoto T; Akiba J; Koga H; Nakamura K; Tokunaga Y; Hanada S; Kumemura H; Maeyama M; Harada M; Ogata H; Yano H; Kojiro M; Ueno T; Yoshimura A; Sata M
Oncogene; 2006 Oct; 25(45):6056-66. PubMed ID: 16652141
[TBL] [Abstract][Full Text] [Related]
13. ECT2 regulates the Rho/ERK signalling axis to promote early recurrence in human hepatocellular carcinoma.
Chen J; Xia H; Zhang X; Karthik S; Pratap SV; Ooi LL; Hong W; Hui KM
J Hepatol; 2015 Jun; 62(6):1287-95. PubMed ID: 25617497
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model.
Feng YX; Wang T; Deng YZ; Yang P; Li JJ; Guan DX; Yao F; Zhu YQ; Qin Y; Wang H; Li N; Wu MC; Wang HY; Wang XF; Cheng SQ; Xie D
Hepatology; 2011 Feb; 53(2):483-92. PubMed ID: 21274870
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-30a suppresses tumor progression by blocking Ras/Raf/MEK/ERK signaling pathway in hepatocellular carcinoma.
Zhou K; Luo X; Wang Y; Cao D; Sun G
Biomed Pharmacother; 2017 Sep; 93():1025-1032. PubMed ID: 28732393
[TBL] [Abstract][Full Text] [Related]
16. Caveolin-1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis.
Tse EY; Ko FC; Tung EK; Chan LK; Lee TK; Ngan ES; Man K; Wong AS; Ng IO; Yam JW
J Pathol; 2012 Mar; 226(4):645-53. PubMed ID: 22072235
[TBL] [Abstract][Full Text] [Related]
17. B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence.
Sun TW; Gao Q; Qiu SJ; Zhou J; Wang XY; Yi Y; Shi JY; Xu YF; Shi YH; Song K; Xiao YS; Fan J
Cancer Immunol Immunother; 2012 Nov; 61(11):2171-82. PubMed ID: 22729558
[TBL] [Abstract][Full Text] [Related]
18. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma.
Nakanishi K; Sakamoto M; Yamasaki S; Todo S; Hirohashi S
Cancer; 2005 Jan; 103(2):307-12. PubMed ID: 15593087
[TBL] [Abstract][Full Text] [Related]
19. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
20. Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways.
Chen SL; Liu LL; Wang CH; Lu SX; Yang X; He YF; Zhang CZ; Yun JP
Mol Oncol; 2020 Feb; 14(2):373-386. PubMed ID: 31670863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
